BackAltamira Therapeutics Overview

Altamira Therapeutics Long Term Debt

Track Altamira Therapeutics's long-term debt ($240K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$238691.00

Peer trimmed avg / median

Loading

Altamira Therapeutics Long Term Debt History

Loading

Altamira Therapeutics vs. peers: Long Term Debt Comparison

Loading

Altamira Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Altamira Therapeutics (CYTO) FAQ

Altamira Therapeutics (CYTO) currently reports a long-term debt of $240K as of December 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Altamira Therapeutics's long-term debt history and peer comparisons.

Altamira Therapeutics's long-term debt changed from $0 to $240K (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Altamira Therapeutics reported $240K in long-term debt as of December 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $240K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Altamira Therapeutics, and consider following CYTO for alerts when major investors trade the stock.

Altamira Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $240K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTO with unrelated industries.